North East and North Cumbria
ICS Formulary
ICS Formulary
8 Malignant disease and immunosuppression
08-02-04 Fingolimod
Links
Cancer Drug Fund List
Disease Modifying Therapies for Patients with Multiple Sclerosis (MS)- Disease Modifying Therapies for Patients with Multiple Sclerosis (MS)
- Disease Modifying Therapies for Patients with Multiple Sclerosis (MS)
- Disease Modifying Therapies for Patients with Multiple Sclerosis (MS)
- Disease Modifying Therapies for Patients with Multiple Sclerosis (MS)
- Letter sent to healthcare professionals (Jan 2016): Fingolimod (Gilenya▼): risks related to effects on the immune system
- Letter sent to healthcare professionals (Nov 2016): lenalidomide (Revlimid▼): new advice about viral reactivation
- Letter sent to healthcare professionals in June 2016: Thalidomide Celgene®: New important advice regarding viral reactivation and pulmonary hypertension
- MHRA Drug Safety Update (Apr 2016): Fingolimod (Gilenya▼): risks of progressive multifocal leukoencephalopathy, basal-cell carcinoma, and opportunistic infections
- MHRA Drug Safety Update (Apr 2016): Natalizumab (Tysabri▼): progressive multifocal leukoencephalopathy— updated advice to support early detection
- MHRA Drug Safety Update (Apr 2017): Multiple sclerosis therapies: signal of rebound effect after stopping or switching therapy
- MHRA Drug safety Update (April 2016): Dimethyl fumarate (Tecfidera): updated advice on risk of progressive multifocal leukoencephalopathy.
- MHRA Drug Safety Update (Dec 2017): Fingolimod (Gilenya▼): new contraindications in relation to cardiac risk
- MHRA Drug Safety Update (Dec 2017): Fingolimod (Gilenya▼): updated advice about risk of cancers and serious infections
- MHRA Drug Safety Update (December 2015): Thalidomide: reduced starting dose in patients older than age 75 years
- MHRA Drug Safety Update (Feb 2011): Lenalidomide: risk of thrombosis and thromboembolism
- MHRA Drug Safety Update (Jan 2013): Lenalidomide (Revlimid): risk of serious hepatic adverse drug reactions
- MHRA Drug Safety Update (Jan 2021): Fingolimod (Gilenya▼): updated advice about the risks of serious liver injury and herpes meningoencephalitis
- MHRA Drug Safety Update (January 2021): Dimethyl fumarate (Tecfidera): updated advice on the risk of progressive multifocal leukoencephalopathy (PML) associated with mild lymphopenia
- MHRA Drug Safety Update (July 2011): Thalidomide: risk of arterial and venous thromboembolism
- MHRA Drug Safety Update (March 2015): Dimethyl fumarate (Tecfidera): fatal PML in an MS patient with severe, prolonged lymphopenia
- MHRA Drug Safety Update (May 2011): Natalizumab (Tysabri▼): risk of progressive multifocal leukoencephalopathy is increased in patients who have had previous immunosuppressant treatment
- MHRA Drug Safety Update (May 2013): Thalidomide: risk of second primary malignancies
- MHRA Drug Safety Update (May 2020): Immunomodulatory drugs and pregnancy prevention: temporary advice for management during coronavirus (COVID-19)
- MHRA Drug Safety Update (May 2020): Immunomodulatory drugs and pregnancy prevention: temporary advice for management during coronavirus (COVID-19)
- MHRA Drug Safety Update (Nov 2011): Lenalidomide (Revlimid▼): update on risk of second primary malignancy
- MHRA Drug Safety Update (Oct 2014): risk of thrombotic microangiopathy and risk of nephrotic syndrome
- MHRA Drug Safety Update (Oct 2014): risk of thrombotic microangiopathy and risk of nephrotic syndrome
- MHRA Drug Safety Update (Oct 2014): risk of thrombotic microangiopathy and risk of nephrotic syndrome
- MHRA Drug Safety Update (Oct 2014): risk of thrombotic microangiopathy and risk of nephrotic syndrome
- MHRA Drug Safety Update (Oct 2020): Niraparib (Zejula▼): reports of severe hypertension and posterior reversible encephalopathy syndrome (PRES), particularly in early treatment
- MHRA Drug Safety Update (Sept 2019): Fingolimod (Gilenya▼): increased risk of congenital malformations; new contraindication during pregnancy and in women of childbearing potential not using effective contraception
- NICE CG165: Hepatitis B (chronic): diagnosis and management
- NICE TA 653: Osimertinib for treating EGFR T790M mutation-positive advanced non-small-cell lung cancer
- NICE TA106: Hepatitis C - peginterferon alfa & ribavirin
- NICE TA127: Natalizumab for the treatment of adults with highly active relapsing–remitting multiple sclerosis
- NICE TA171: Lenalidomide for the treatment of multiple myeloma in people who have received at least 2 prior therapies
- NICE TA200: Hepatitis C - peginterferon alfa & ribavirin
- NICE TA228: Bortezomib and thalidomide for the first‑line treatment of multiple myeloma
- NICE TA235: Osteosarcoma - mifamurtide: guidance
- NICE TA254: Fingolimod for highly active relapsing remitting multiple sclerosis
- NICE TA27: Lenalidomide with rituximab for previously treated follicular lymphoma
- NICE TA300: Hepatitis C - peginterferon alfa
- NICE TA303: Teriflunomide for treating relapsing–remitting multiple sclerosis
- NICE TA320: Dimethyl fumarate for multiple sclerosis
- NICE TA322: Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality
- NICE TA427: Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib
- NICE TA450 Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia
- NICE TA527: Beta interferons and glatiramer acetate for treating multiple sclerosis
- NICE TA527: Beta interferons and glatiramer acetate for treating multiple sclerosis
- NICE TA527: Beta interferons and glatiramer acetate for treating multiple sclerosis
- NICE TA527: Beta interferons and glatiramer acetate for treating multiple sclerosis
- NICE TA527: Beta interferons and glatiramer acetate for treating multiple sclerosis
- NICE TA586: Lenalidomide plus dexamethasone for multiple myeloma after 1 treatment with bortezomib
- NICE TA587: Lenalidomide plus dexamethasone for previously untreated multiple myeloma
- NICE TA589: Blinatumomab for treating acute lymphoblastic leukaemia in remission with minimal residual disease activity
- NICE TA624: Peginterferon beta-1a for treating relapsing–remitting multiple sclerosis
- NICE TA654: Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer
- NICE TA656: Siponimod for treating secondary progressive multiple sclerosis
- NICE TA680: Lenalidomide maintenance treatment after an autologous stem cell transplant for newly diagnosed multiple myeloma
- NICE TA75: Hepatitis C - pegylated interferons, ribavirin & alfa interferon
- NICE TA761 Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection
- NICE TA767: Ponesimod for treating relapsing–remitting multiple sclerosis
- NICE TA789: Tepotinib for treating advanced non-small-cell lung cancer with MET gene alterations
- NICE TA794: Diroximel fumarate for treating relapsing–remitting multiple sclerosis
- NICE TA96: Hepatitis B - peginterferon alfa
- Northern Cancer Alliance
- Northern England Clinical Networks Palliative and End of Life Care Guidelines